Your browser is no longer supported. Please, upgrade your browser.
Settings
ONTX Onconova Therapeutics, Inc. daily Stock Chart
ONTX [NASD]
Onconova Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.71 Insider Own5.30% Shs Outstand9.19M Perf Week-6.22%
Market Cap18.01M Forward P/E- EPS next Y-2.33 Insider Trans48.92% Shs Float7.38M Perf Month-7.98%
Income-19.70M PEG- EPS next Q-0.73 Inst Own15.50% Short Float4.33% Perf Quarter-30.74%
Sales5.50M P/S3.27 EPS this Y57.90% Inst Trans-3.91% Short Ratio1.74 Perf Half Y-37.38%
Book/sh-0.52 P/B- EPS next Y29.40% ROA-98.80% Target Price8.00 Perf Year-53.22%
Cash/sh1.68 P/C1.17 EPS next 5Y- ROE-744.50% 52W Range1.95 - 8.17 Perf YTD-13.66%
Dividend- P/FCF- EPS past 5Y50.00% ROI-551.60% 52W High-76.01% Beta0.11
Dividend %- Quick Ratio1.70 Sales past 5Y30.10% Gross Margin- 52W Low0.51% ATR0.12
Employees23 Current Ratio1.70 Sales Q/Q-86.70% Oper. Margin- RSI (14)31.73 Volatility5.25% 5.57%
OptionableNo Debt/Eq- EPS Q/Q53.50% Profit Margin- Rel Volume0.40 Prev Close1.98
ShortableYes LT Debt/Eq- EarningsMay 15 BMO Payout- Avg Volume184.20K Price1.96
Recom2.00 SMA20-6.54% SMA50-21.27% SMA200-27.97% Volume73,421 Change-1.01%
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
May-22-17 08:30AM  Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association GlobeNewswire
May-19-17 08:55PM  Edited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT Thomson Reuters StreetEvents
May-18-17 08:30AM  Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-15-17 08:30AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results GlobeNewswire
08:00AM  Investor Network: Onconova Therapeutics Inc. to Host Earnings Call Accesswire
May-04-17 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results GlobeNewswire
May-01-17 08:31AM  Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes GlobeNewswire +5.38%
Apr-26-17 05:26PM  Onconova Therapeutics Announces Closing of Public Offering of Common Stock GlobeNewswire
08:30AM  Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC GlobeNewswire
Apr-21-17 09:55AM  Onconova Therapeutics stock drops 12% after pricing stock offering MarketWatch -15.26%
09:41AM  Onconova Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Apr-20-17 07:47PM  Onconova Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-05-17 11:22AM  Company News for April 05, 2017 Zacks
11:22AM  Company News for April 05, 2017
08:30AM  Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval Accesswire
08:30AM  Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval
Apr-04-17 12:25PM  Onconova Reports Positive Data for 2 Cancer Drugs Investopedia +6.98%
12:25PM  Onconova Reports Positive Data for 2 Cancer Drugs
09:08AM  Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs MarketWatch
09:08AM  Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs
08:46AM  Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting GlobeNewswire
08:46AM  Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting
Mar-31-17 09:28AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017 Capital Cube
09:28AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
Mar-29-17 05:20PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report +7.34%
Mar-28-17 07:41AM  Edited Transcript of ONTX earnings conference call or presentation 27-Mar-17 1:00pm GMT Thomson Reuters StreetEvents
07:41AM  Edited Transcript of ONTX earnings conference call or presentation 27-Mar-17 1:00pm GMT
Mar-27-17 08:51AM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:07AM  Q4 2016 Onconova Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results GlobeNewswire
Mar-21-17 08:30AM  Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences GlobeNewswire
Mar-16-17 08:30AM  Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2016 Financial Results GlobeNewswire
Mar-02-17 08:30AM  Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March GlobeNewswire
Feb-09-17 08:30AM  Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February GlobeNewswire
Jan-27-17 12:17PM  These 5 Stocks Under $10 Could Get Hot Soon
08:30AM  Onconova Therapeutics, Inc. to Present at NobleCON13 GlobeNewswire
Jan-12-17 09:00AM  SeeThruEquity Initiates Coverage on Onconova Therapeutics, Inc. (NASDAQ: ONTX) with a Price Target of $5.00 Accesswire
Jan-10-17 08:30AM  Onconova Therapeutics, Inc. Discusses Target Indications and Clinical Development in New SNNLive Video Interview on StockNewsNow.com PR Newswire +31.95%
Jan-05-17 08:30AM  Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017 GlobeNewswire
Dec-15-16 05:11PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-06-16 07:01AM  Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting GlobeNewswire
Dec-05-16 08:32AM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
07:01AM  Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting GlobeNewswire
Nov-23-16 01:04PM  ONCONOVA THERAPEUTICS, INC. Financials
Nov-21-16 11:39AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 -6.86%
Nov-14-16 03:04PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +11.03%
07:01AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results GlobeNewswire
Nov-04-16 07:01AM  Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting GlobeNewswire
Oct-13-16 07:01AM  Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum GlobeNewswire
Oct-10-16 08:53AM  Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in Oncology on Monday, October 17, in New York City GlobeNewswire
Sep-27-16 11:17AM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:13AM  ETFs with exposure to Onconova Therapeutics, Inc. : September 27, 2016
Sep-26-16 07:01AM  Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination GlobeNewswire
Sep-07-16 07:01AM  Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences GlobeNewswire
Sep-01-16 07:50AM  More job cuts at Bucks County biopharm firm at bizjournals.com
Aug-30-16 05:12PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Director
11:24AM  ETFs with exposure to Onconova Therapeutics, Inc. : August 30, 2016
Aug-19-16 01:07PM  ETFs with exposure to Onconova Therapeutics, Inc. : August 19, 2016
Aug-18-16 11:55AM  5 Breakout Stocks Under $10 Set to Soar
11:20AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-15-16 09:03AM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:01AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results GlobeNewswire
Aug-12-16 07:22AM  7 Stocks Under $10 Making Big Up Moves
Aug-11-16 09:20AM  Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2016 Financial Results GlobeNewswire +6.83%
Aug-01-16 08:01AM  Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million GlobeNewswire -6.11%
Jul-27-16 09:20AM  Onconova Announces Expiration of Oversubscribed Rights Offering GlobeNewswire
Jul-22-16 05:53PM  Onconova Adjusts Pricing of Rights Offering GlobeNewswire
Jul-19-16 07:01AM  Onconova Announces Enrollment of First Patient in Japan by SymBio GlobeNewswire
Jul-13-16 04:53PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Jul-08-16 09:20AM  Onconova Announces Commencement of Subscription Period for Previously Announced Rights Offering GlobeNewswire -5.81%
Jul-01-16 07:01AM  Onconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016 GlobeNewswire
Jun-29-16 06:01PM  Onconova Announces Price Range and Change of Key Dates for Rights Offering GlobeNewswire
Jun-20-16 08:45AM  Onconova Informs Stockholders of Key Dates Related to Announced Rights Offering GlobeNewswire +5.70%
Jun-13-16 08:01AM  Onconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting GlobeNewswire
Jun-08-16 07:17AM  6 Stocks Under $10 Making Big Moves Higher +7.25%
Jun-06-16 05:39PM  ETFs with exposure to Onconova Therapeutics, Inc. : June 6, 2016 +11.17%
05:00PM  Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting GlobeNewswire
Jun-02-16 09:36AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -9.21%
Jun-01-16 06:30PM  Onconova Files S-1 Registration Statement for Rights Offering to Shareholders GlobeNewswire +8.57%
May-31-16 04:08PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Ar +5.66%
08:45AM  Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting GlobeNewswire
07:03AM  Splits Calendar: Onconova Therapeutics splits before market open today (1:10 ratio)
May-23-16 04:21PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
08:01AM  Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors GlobeNewswire
May-20-16 08:01AM  Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split GlobeNewswire -24.96%
May-12-16 04:50PM  ETFs with exposure to Onconova Therapeutics, Inc. : May 12, 2016
May-11-16 04:13PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +16.71%
04:05PM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results GlobeNewswire
Apr-29-16 03:16PM  ETFs with exposure to Onconova Therapeutics, Inc. : April 29, 2016
Apr-21-16 07:00PM  Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell GlobeNewswire
Apr-20-16 08:30AM  Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting GlobeNewswire
Apr-04-16 03:37PM  ETFs with exposure to Onconova Therapeutics, Inc. : April 4, 2016 -15.48%
Apr-01-16 11:24AM  Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-28-16 08:31AM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +6.39%
08:11AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results at noodls
08:01AM  Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results GlobeNewswire
Mar-23-16 09:30AM  Onconova Starts Phase III INSPIRE Study on Rigosertib in EU +17.37%
Mar-21-16 07:17AM  Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes at noodls +17.84%
07:01AM  Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes GlobeNewswire
Mar-09-16 05:22PM  ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bienen Henry SDirectorApr 26Buy2.103,8108,00112,724Apr 28 03:12 PM
Guerin Mark PatrickChief Financial OfficerApr 26Buy2.101,4293,0015,155Apr 28 03:11 PM
Reddy E PremkumarDirectorApr 26Buy2.10119,048250,001385,832Apr 28 03:03 PM
MARINO JAMES JDirectorApr 26Buy2.1011,90625,00336,321Apr 28 03:04 PM
Kumar RameshPresident and CEOApr 26Buy2.1023,81050,001102,227Apr 28 03:03 PM
Maniar ManojSVP - Product DevelopmentJun 30Option Exercise6.505032550Jun 30 05:24 PM
GROOPMAN JEROMEDirectorJun 29Option Exercise5.20105210Aug 10 08:39 PM
MARINO JAMES JDirectorJun 27Option Exercise5.20105210Jun 29 09:08 PM
Fruchtman Steven MChief Medical OfficerJun 24Option Exercise6.50100650100Jun 30 05:26 PM